{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-054484","form_type":"8-K","ticker":"AKTX","cik":"0001541157","company_name":"Akari Therapeutics Plc","filed_at":"2025-04-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.702750+00:00","generated_at":"2026-05-23T13:23:55.604966+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Akari Therapeutics FY2024 net loss $21.6M; cash runway into Sep 2025; new CEO named","bullets":["FY2024 net loss from operations $21.6M vs $16.8M in 2023; R&D $7.0M, G&A $9.7M.","Cash $2.6M at Dec 31, 2024; plus $6.6M private placement in March 2025 funds operations into Sep 2025.","Lead ADC AKTX-101 (TROP2 PH1) for solid tumors; seeking licensing/strategic partner.","Abizer Gaslightwala named President and CEO effective April 21, 2025.","Merger with Peak Bio completed Nov 2024; pipeline focused on next-gen bifunctional ADCs."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-054484","json":"https://secwatch.observer/filing/0000950170-25-054484.json","markdown":"https://secwatch.observer/filing/0000950170-25-054484.md","text":"https://secwatch.observer/filing/0000950170-25-054484.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025054484/0000950170-25-054484-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025054484/aktx-20250416.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T13:23:55.604966+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}